KPTI News and Press, Karyopharm Therapeutics Inc. From 02/08/23

Karyopharm to Report Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023 PR Newswire -- Conference Call Scheduled for Wednesday, February 15, 2023 , at 8:00 a.m. ET -- NEWTON, Mass. , Feb. 8, 2023 /PRNewswire/ -- Karyopharm Th...

Karyopharm Therapeutics ( NASDAQ: KPTI ) added ~5% pre-market Thursday after Piper Sandler launched its coverage with an Overweight recommendation citing the potential of the company’s FDA-approved cancer therapy Xpovio. The treatment is currently indicated with dexamethaso...

The following slide deck was published by Karyopharm Therapeutics Inc. in conjunction with this event. For further details see: Karyopharm Therapeutics (KPTI) Presents at the 41st Annual J.P. Morgan Healthcare Conference -- Slideshow

Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue and Outlines 2023 Objectives PR Newswire – Preliminary Unaudited Full Year 2022 Total Revenue and U.S. XPOVIO ® (selinexor) Net Product Revenue Expected to be Appro...

Karyopharm to Present at 41st Annual J.P. Morgan Healthcare Conference PR Newswire NEWTON, Mass. , Jan. 4, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announc...

Summary Karyopharm is still reporting growth, but the market continues to punish KPTI to fresh 52-week lows. I take a look at the company's Q3 earnings report. XPOVIO delivered strong year-over-year growth with $32M, up from $26.7M in Q3 of last year, representing 20% growth year-over-y...

Summary Karyopharm Therapeutics hasn't done a lot of impressive stuff in the last 6 months. It is trading at 52-week lows, but that may not be a good thing by itself. I will stay on the sidelines, because I am unable to see the value here. I covered Karyopharm Therapeu...

Karyopharm Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Naïve Myelofibrosis at ASH 2022 PR Newswire – A 92% SVR35 and a 67% TSS50 were Observed in the Efficacy Evaluable Patients at Week 24 – – 57% of Tra...

Karyopharm Announces $165 Million Private Placement PR Newswire NEWTON, Mass. , Dec. 5, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has ente...

Karyopharm Announces Investor and Analyst Event at ASH 2022 on Selinexor Data in Patients with Treatment-Naïve Myelofibrosis PR Newswire – Key Opinion Leaders to Review Highlights from Updated Phase 1 Data to be Presented at ASH 2022 at Company Sponsored Event on ...